First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples